Prostaglandin F2-alpha eye drops (BIMAtoprost) in thyroid eye disease: a randomised controlled double blind crossover trial

Cardiff University (UK)0 个研究点目标入组 31 人开始时间: 2014年3月14日最近更新: 2019年9月2日

适应症

试验速览

•1. Stable TED with no reported change in proptosis for at least 6 months
•2. Clinical activity score <3
•3. Proptosis (subjective unilateral proptosis confirmed by asymmetry in exophthalmometry of >2 mm OR greater than 20 mm on exophthalmometry measurement in one eye)
•4. Euthyroid (FT3 and FT4 in the reference range)
•5. If female, must be using a reliable form of contraception during the trial, e.g. oral contraceptive and condom, intrauterine device (IUD) and condom, diaphragm with spermicide and condom

•1. Age <18 years
•2. Dysthyroid optic neuropathy unless previously treated
•3. Pregnancy or lactation
•4. Previous corneal herpes simplex infection
•5. On therapy for glaucoma or intraocular hypertension
•6. Less than 6 months from prior steroid use
•7. Aphakia, pseudophakia with torn posterior lens capsule or anterior chamber lenses
•8. Patient with risk factors for cystoid macular oedema, iritis or uveitis
•9. Severe asthma (risk of severe allergic reaction to medication).
•10. Previous allergy to Bimatoprost or preservative

发起方

Cardiff University (UK)